Form 4: Structure Therapeutics CEO Raymond Stevens Reports Share Vesting, Tax Withholdings, and ESPP Acquisition

Structure Therapeutics Inc.'s CEO and Director, Raymond C. Stevens, reported multiple transactions including the vesting of performance-based restricted share units, shares withheld for tax obligations, and an acquisition through the Employee Share Purchase Plan.

Summary

• Raymond C. Stevens, CEO and Director of Structure Therapeutics Inc., reported changes in his beneficial ownership of the company's securities.
• On March 1, 2025, 12,495 Ordinary Shares were disposed of at a price of $7.9166 per share to satisfy income tax obligations related to the vesting of a restricted share unit award.
• On July 1, 2025, 89,697 Ordinary Shares were acquired at a price of $0 due to the vesting of performance-vesting restricted share units (PSUs). These PSUs were granted on March 15, 2024, with 50% vesting on July 1, 2025, and the remaining 50% scheduled to vest on January 1, 2027, contingent on continuous service.
• Also on July 1, 2025, an additional 16,050 Ordinary Shares were disposed of at a price of $6.8366 per share to cover income tax obligations associated with the vesting of a restricted share unit award.
• On May 21, 2025, 1,000 American Depositary Shares (ADSs) were acquired at a price of $0 through the Issuer's Employee Share Purchase Plan (ESPP). Each ADS represents three Ordinary Shares.
• Following these transactions, Raymond C. Stevens directly holds 1,194,830 Ordinary Shares and 1,000 American Depositary Shares.
• Indirectly, he holds 1,554,586 Ordinary Shares and 4,000 American Depositary Shares through the Stevens 2001 Revocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there are share disposals, they are for tax purposes, which is a neutral event. The significant acquisition of shares through PSU vesting indicates performance criteria were met, and the ESPP acquisition shows continued insider investment, both of which are positive signals.

Positives

• Acquisition of 89,697 Ordinary Shares from the vesting of performance-vesting restricted share units (PSUs), indicating the achievement of certain performance criteria.
• Acquisition of 1,000 American Depositary Shares (equivalent to 3,000 Ordinary Shares) through the Employee Share Purchase Plan (ESPP), demonstrating continued investment by the CEO.

Negatives

• Disposal of 12,495 Ordinary Shares at $7.9166 and 16,050 Ordinary Shares at $6.8366 to satisfy income tax obligations, which are non-discretionary sales.

Future Outlook

The remaining 50% of the performance-vesting restricted share units (PSUs) granted on March 15, 2024, are scheduled to vest on January 1, 2027, contingent on the reporting person's continuous service.

Industry Context

This Form 4 filing details routine insider transactions for a biotechnology company's CEO, including equity compensation vesting and tax-related share disposals, which are common occurrences across the industry for executive compensation.

Related Party Transactions

• Indirect beneficial ownership of 1,554,586 Ordinary Shares and 4,000 American Depositary Shares (representing 12,000 Ordinary Shares) is held by Raymond Stevens and Vivian Urena-Stevens as Co-Trustees of the Stevens 2001 Revocable Trust, dated March 28, 2001.

Stakeholder Impact

• Shareholders: The vesting of performance-based equity awards for the CEO aligns management incentives with shareholder value creation. The tax-related sales are routine and do not reflect a change in investment conviction. The ESPP acquisition shows continued insider confidence.
• Employees: The Employee Share Purchase Plan (ESPP) mentioned indicates a benefit available to employees, fostering broader employee ownership.

Next Steps

• The remaining 50% of the performance-vesting restricted share units (PSUs) are scheduled to vest on January 1, 2027, subject to the CEO's continuous service.

Key Dates

Recommendation

Keywords

Structure Therapeutics Inc., GPCR, Raymond C. Stevens, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Share Units, Performance Share Units, Employee Share Purchase Plan, ADS, Ordinary Shares, Executive Compensation, Tax Withholding